Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H2 2019’, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections

– The report reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Vancomycin-Resistant Enterococcus faecium Infections therapeutics and enlists all their major and minor projects

– The report assesses Vancomycin-Resistant Enterococcus faecium Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Acurx Pharmaceuticals LLC

AimMax Therapeutics Inc

Alchemia Ltd

AnyGen Co Ltd

Aphios Corp

Arietis Corp

Armata Pharmaceuticals Inc

AzurRx BioPharma Inc

Curza Global LLC

Daiichi Sankyo Co Ltd

Ferring International Center SA

Helix BioMedix Inc

Hsiri Therapeutics LLC

Karveel Pharmaceuticals

MGB Biopharma Ltd

MicuRx Pharmaceuticals Inc

Naicons Srl

NovoBiotic Pharmaceuticals LLC

Opal Biosciences Ltd

Oragenics Inc

Ovensa Inc

Sealife PHARMA GMBH

Sentinella Pharmaceuticals Inc

Wockhardt Ltd”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Vancomycin-Resistant Enterococcus faecium Infections Overview 5

Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Development 6

Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Assessment 15

Vancomycin-Resistant Enterococcus faecium Infections Companies Involved in Therapeutics Development 23

Vancomycin-Resistant Enterococcus faecium Infections Drug Profiles 30

Vancomycin-Resistant Enterococcus faecium Infections Dormant Projects 74

Vancomycin-Resistant Enterococcus faecium Infections Discontinued Products 77

Vancomycin-Resistant Enterococcus faecium Infections Product Development Milestones 78

Appendix 81

List of Tables

“List of Tables

Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Acurx Pharmaceuticals LLC, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by AimMax Therapeutics Inc, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Alchemia Ltd, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by AnyGen Co Ltd, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Aphios Corp, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Arietis Corp, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Armata Pharmaceuticals Inc, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by AzurRx BioPharma Inc, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Curza Global LLC, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Daiichi Sankyo Co Ltd, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Ferring International Center SA, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Helix BioMedix Inc, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Hsiri Therapeutics LLC, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Karveel Pharmaceuticals, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by MGB Biopharma Ltd, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by MicuRx Pharmaceuticals Inc, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Naicons Srl, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by NovoBiotic Pharmaceuticals LLC, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Opal Biosciences Ltd, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Oragenics Inc, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Ovensa Inc, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Sealife PHARMA GMBH, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Sentinella Pharmaceuticals Inc, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Wockhardt Ltd, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Dormant Projects, H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Dormant Projects, H2 2019 (Contd..1), H2 2019

Vancomycin-Resistant Enterococcus faecium Infections – Discontinued Products, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports